168 related articles for article (PubMed ID: 22723123)
1. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
Zhu R; Cheng KW; Mackenzie G; Huang L; Sun Y; Xie G; Vrankova K; Constantinides PP; Rigas B
Pharm Res; 2012 Nov; 29(11):3090-101. PubMed ID: 22723123
[TBL] [Abstract][Full Text] [Related]
2. Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.
Cheng KW; Wong CC; Mattheolabakis G; Xie G; Huang L; Rigas B
Int J Oncol; 2013 Sep; 43(3):895-902. PubMed ID: 23807084
[TBL] [Abstract][Full Text] [Related]
3. Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.
Cheng KW; Wong CC; Alston N; Mackenzie GG; Huang L; Ouyang N; Xie G; Wiedmann T; Rigas B
Mol Cancer Ther; 2013 Aug; 12(8):1417-28. PubMed ID: 23645590
[TBL] [Abstract][Full Text] [Related]
4. Phospho-Sulindac (OXT-328) Inhibits Dry Eye Disease in Rabbits: A Dose-, Formulation- and Structure-Dependent Effect.
Huang W; Wen Z; Saglam MS; Huang L; Honkanen RA; Rigas B
J Ocul Pharmacol Ther; 2021; 37(6):321-330. PubMed ID: 34152861
[No Abstract] [Full Text] [Related]
5. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
Wen Z; Muratomi N; Huang W; Huang L; Ren J; Yang J; Persaud Y; Loloi J; Mallangada N; Kung P; Honkanen R; Rigas B
Int J Pharm; 2019 Feb; 557():273-279. PubMed ID: 30597269
[TBL] [Abstract][Full Text] [Related]
6. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo.
Wang P; Zhang L; Peng H; Li Y; Xiong J; Xu Z
Mater Sci Eng C Mater Biol Appl; 2013 Dec; 33(8):4802-8. PubMed ID: 24094190
[TBL] [Abstract][Full Text] [Related]
7. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
Xie G; Nie T; Mackenzie GG; Sun Y; Huang L; Ouyang N; Alston N; Zhu C; Murray OT; Constantinides PP; Kopelovich L; Rigas B
Br J Pharmacol; 2012 Apr; 165(7):2152-66. PubMed ID: 21955327
[TBL] [Abstract][Full Text] [Related]
8. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.
Cheng KW; Mattheolabakis G; Wong CC; Ouyang N; Huang L; Constantinides PP; Rigas B
Int J Oncol; 2012 Oct; 41(4):1199-203. PubMed ID: 22842609
[TBL] [Abstract][Full Text] [Related]
9. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Mackenzie GG; Sun Y; Huang L; Xie G; Ouyang N; Gupta RC; Johnson F; Komninou D; Kopelovich L; Rigas B
Gastroenterology; 2010 Oct; 139(4):1320-32. PubMed ID: 20600034
[TBL] [Abstract][Full Text] [Related]
10. A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.
Cheng KW; Nie T; Ouyang N; Alston N; Wong CC; Mattheolabakis G; Papayannis I; Huang L; Rigas B
Int J Pharm; 2014 Dec; 477(1-2):236-43. PubMed ID: 25311177
[TBL] [Abstract][Full Text] [Related]
11. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.
Zhu C; Cheng KW; Ouyang N; Huang L; Sun Y; Constantinides P; Rigas B
Stem Cells; 2012 Oct; 30(10):2065-75. PubMed ID: 22653497
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Alsaidan YSM; Alfaiz SA; Haque A; Az A; Alhazzani K
Chem Phys Lipids; 2020 Nov; 233():105003. PubMed ID: 33096096
[TBL] [Abstract][Full Text] [Related]
13. Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting.
Swami R; Singh I; Jeengar MK; Naidu VG; Khan W; Sistla R
Int J Pharm; 2015; 486(1-2):287-96. PubMed ID: 25839415
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents.
Sun Y; Huang L; Mackenzie GG; Rigas B
J Pharmacol Exp Ther; 2011 Sep; 338(3):775-83. PubMed ID: 21646387
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells.
da Rocha MCO; da Silva PB; Radicchi MA; Andrade BYG; de Oliveira JV; Venus T; Merker C; Estrela-Lopis I; Longo JPF; Báo SN
J Nanobiotechnology; 2020 Mar; 18(1):43. PubMed ID: 32164731
[TBL] [Abstract][Full Text] [Related]
17. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
[TBL] [Abstract][Full Text] [Related]
18. Topical Skin Cancer Therapy Using Doxorubicin-Loaded Cationic Lipid Nanoparticles and lontophoresis.
Huber LA; Pereira TA; Ramos DN; Rezende LC; Emery FS; Sobral LM; Leopoldino AM; Lopez RF
J Biomed Nanotechnol; 2015 Nov; 11(11):1975-88. PubMed ID: 26554156
[TBL] [Abstract][Full Text] [Related]
19. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis.
Wang H; Zhang F; Wen H; Shi W; Huang Q; Huang Y; Xie J; Li P; Chen J; Qin L; Zhou Y
J Nanobiotechnology; 2020 Jan; 18(1):8. PubMed ID: 31918714
[TBL] [Abstract][Full Text] [Related]
20. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.
Oida Y; Gopalan B; Miyahara R; Inoue S; Branch CD; Mhashilkar AM; Lin E; Bekele BN; Roth JA; Chada S; Ramesh R
Mol Cancer Ther; 2005 Feb; 4(2):291-304. PubMed ID: 15713900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
